Published in Gut on November 01, 2001
TPMT in the treatment of Crohn's disease with azathioprine. Gut (2002) 1.79
Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut (2001) 1.11
The thiopurines: an update. Invest New Drugs (2005) 1.05
Implementation of TPMT testing. Br J Clin Pharmacol (2014) 0.96
Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol (2006) 0.90
Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut (2004) 0.88
Medical treatment of ulcerative colitis. Clin Colon Rectal Surg (2004) 0.86
Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig Dis Sci (2007) 0.86
Therapeutic drug monitoring in patients with inflammatory bowel disease. World J Gastroenterol (2014) 0.84
Thiopurine methyltransferase (TPMT) genotype distribution in azathioprine-tolerant and -intolerant patients with various disorders. The impact of TPMT genotyping in predicting toxicity. Eur J Clin Pharmacol (2003) 0.83
Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease. World J Gastroenterol (2009) 0.80
Thiopurine monitoring in children with inflammatory bowel disease: a systematic review. Br J Clin Pharmacol (2014) 0.79
The Role of Laboratory Tests in Crohn's Disease. Clin Med Insights Gastroenterol (2016) 0.76
Two cases of thiopurine methyltransferase (TPMT) deficiency--a lucky save and a near miss with azathioprine. Br J Clin Pharmacol (2006) 0.76
Medical approaches and future options in chronic active ulcerative colitis. Int J Colorectal Dis (2004) 0.76
Prospective Evaluation of Pharmacogenomics and Metabolite Measurements upon Azathioprine Therapy in Inflammatory Bowel Disease: An Observational Study. Medicine (Baltimore) (2016) 0.75
Suspected azathioprine induced liver cirrhosis: an unusual side effect. Pan Afr Med J (2014) 0.75
Thiopurine metabolites and the role of thiopurine methyltransferase activity in inflammatory bowel disease. Gut (2002) 0.75
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. Eur J Clin Pharmacol (2015) 0.75
Thioguanine in inflammatory bowel disease: Long-term efficacy and safety. United European Gastroenterol J (2016) 0.75
Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet (1980) 3.71
Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology (1994) 3.22
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology (2000) 2.99
Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med (1995) 2.95
The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol (1992) 2.53
Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology (1999) 2.14
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology (1999) 1.84
The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol (1996) 1.83
Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells. J Pharm Pharmacol (1983) 1.79
6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut (1996) 1.76
Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther (1987) 1.62
Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics (1992) 1.26
Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet (1994) 1.24
Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol (1995) 1.23
Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut (2001) 1.11
Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther (1997) 1.10
High-performance liquid chromatographic assay for the determination of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid concentrations in endoscopic intestinal biopsy in humans. J Chromatogr (1991) 0.90
A reversed phase high performance liquid chromatography approach in determining total red blood cell concentrations of 6-thioguanine, 6-mercaptopurine, methylthioguanine, and methylmercaptopurine in a patient receiving thiopurine therapy. Biomed Chromatogr (1990) 0.88
Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts. Ther Drug Monit (1997) 0.85
The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine. Clin Pharmacokinet (1995) 0.84
Effect of food coadministration on 5-aminosalicylic acid oral suspension bioavailability. Clin Pharmacol Ther (1990) 0.80
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med (2000) 10.21
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med (1997) 8.65
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med (1987) 7.73
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis (2000) 6.90
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med (1999) 6.84
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology (1998) 4.52
Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc (2000) 4.45
The frequency of carpal tunnel syndrome in computer users at a medical facility. Neurology (2001) 4.44
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA (1999) 4.25
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 3.85
The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther (2002) 3.71
The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology (2001) 3.60
Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1997) 3.29
A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc (1994) 3.14
Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology (1993) 2.99
Sensitivity and positive predictive value of Medicare Part B physician claims for rheumatologic diagnoses and procedures. Arthritis Rheum (1997) 2.93
Hereditary angioedema: a broad review for clinicians. Arch Intern Med (2001) 2.92
Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut (2000) 2.86
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis (2001) 2.80
Blinded prospective evaluation of sensitivity of MR angiography to known intracranial aneurysms: importance of aneurysm size. AJNR Am J Neuroradiol (1994) 2.59
Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol (1992) 2.54
Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med (1980) 2.51
Molecular evolution of inversions in Drosophila pseudoobscura: the amylase gene region. Proc Natl Acad Sci U S A (1991) 2.48
Lung nodule enhancement at CT: multicenter study. Radiology (2000) 2.32
Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. Cancer (2000) 2.28
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. Aliment Pharmacol Ther (2015) 2.25
Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc (1994) 2.23
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut (2005) 2.22
Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther (2010) 2.20
Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut (2009) 2.20
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther (2014) 2.18
Identification of murine helicobacters by PCR and restriction enzyme analyses. J Clin Microbiol (1996) 2.18
Contralateral adrenal metastasis of renal cell carcinoma: treatment, outcome and a review. BJU Int (2003) 2.17
Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology (1999) 2.14
Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside. Lancet (1978) 2.10
Autologous platelet-rich plasma does not reduce transfusion of homologous blood products in patients undergoing repeat valvular surgery. Anesthesiology (1993) 2.04
Mycophenolate mofetil for Crohn's disease? Lancet (1999) 2.03
Constipation in an elderly community: a study of prevalence and potential risk factors. Am J Gastroenterol (1996) 2.01
Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer. Gynecol Oncol (2012) 2.01
Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther (2013) 1.99
"Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc (1995) 1.97
The spectrum of serous cystadenoma of the pancreas. Clinical, pathologic, and surgical aspects. Ann Surg (1992) 1.96
Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther (2005) 1.96
Lung nodule enhancement at CT: prospective findings. Radiology (1996) 1.85
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology (1999) 1.84
Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol (2001) 1.79
Misdiagnosis of specific cytomegalovirus infection of the ileoanal pouch as refractory idiopathic chronic pouchitis: report of two cases. Dis Colon Rectum (1999) 1.79
Pulmonary nodules: CT evaluation of enhancement with iodinated contrast material. Radiology (1995) 1.78
Ruptured abdominal aortic aneurysms: repair should not be denied. J Vasc Surg (1992) 1.75
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut (2008) 1.75
Functional constipation and outlet delay: a population-based study. Gastroenterology (1993) 1.74
Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol (2000) 1.71
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther (2013) 1.69
Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2013) 1.63
Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterol Motil (2009) 1.62
Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc (1996) 1.61
Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology (1999) 1.61
Morphological and physiological differentiation of Purkinje neurons in cultures of rat cerebellum. J Neurosci (1987) 1.61
Analysis of 281,797 consecutive blood cultures performed over an eight-year period: trends in microorganisms isolated and the value of anaerobic culture of blood. Clin Infect Dis (1997) 1.60
Nonsteroidal anti-inflammatory drug-induced enteropathy: case discussion and review of the literature. Mayo Clin Proc (1995) 1.59
Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med (1984) 1.57
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther (2014) 1.56
Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology (1999) 1.56
Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol (2000) 1.56
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther (2009) 1.54
Cyclosporine therapy for inflammatory bowel disease: definitive answers and remaining questions. Gastroenterology (1995) 1.54
Maintenance of symptomatic remission in patients with Crohn's disease. Mayo Clin Proc (1993) 1.54
Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: A new proposal. Cancer (1999) 1.54
MHC Class II alleles in ulcerative colitis-associated colorectal cancer. Gut (2009) 1.53
Seroanalysis of Tyzzer's disease in horses: implications that multiple strains can infect Equidae. Equine Vet J (1995) 1.52
Fecal PCR assay for diagnosis of Helicobacter infection in laboratory rodents. J Clin Microbiol (1997) 1.51
Long-term cognitive outcomes following out-of-hospital cardiac arrest: a population-based study. Neurology (2011) 1.51
Lung nodules: dual-kilovolt peak analysis with CT--multicenter study. Radiology (2000) 1.49
Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non-human primates. Hum Gene Ther (1995) 1.49
Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc (1996) 1.47
A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology (2001) 1.47
Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J Gastroenterol (2000) 1.46
Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis (2001) 1.46
Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology (1996) 1.46
Early extubation after abdominal aortic reconstruction. J Cardiothorac Vasc Anesth (1998) 1.45
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis (2001) 1.44